APA (7th ed.) Citation

E, T., G, A. T., S, Y., O, K., N, S. B., M, A., . . . N, T. (2025). Comparison of paclitaxel and docetaxel in dual HER2 blockade: Efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer. Breast cancer research and treatment, 211(3), 743. https://doi.org/10.1007/s10549-025-07694-7

Chicago Style (17th ed.) Citation

E, Turkoglu, et al. "Comparison of Paclitaxel and Docetaxel in Dual HER2 Blockade: Efficacy and Safety in Neoadjuvant Treatment of HER2-positive Breast Cancer." Breast Cancer Research and Treatment 211, no. 3 (2025): 743. https://doi.org/10.1007/s10549-025-07694-7.

MLA (9th ed.) Citation

E, Turkoglu, et al. "Comparison of Paclitaxel and Docetaxel in Dual HER2 Blockade: Efficacy and Safety in Neoadjuvant Treatment of HER2-positive Breast Cancer." Breast Cancer Research and Treatment, vol. 211, no. 3, 2025, p. 743, https://doi.org/10.1007/s10549-025-07694-7.